More on CVM
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| NET (LOSS) INCOME | -10.35M |
| Depreciation and amortization | 118.27K |
| Issuance of convertible notes and preferred stock in legal settlement | |
| Issuance of common stock, warrants and stock options for services | 618.89K |
| Common stock contributed to 401(k) plan | |
| Extension of options | |
| Employee option cost | |
| Gain on derivative instruments | |
| Decrease in deferred rent asset | |
| Amortization of loan premium | |
| Loss on abandonment of patents | |
| Loss on retirement of equipment | 115 |
| Increase in prepaid expenses | 267.74K |
| Increase in inventory for R&D and manufacturing | 142.38K |
| Decrease in deposits | |
| Increase in receivables | 5.85K |
| Decrease in accounts payable | -1.08M |
| Increase in accrued expenses | 86.4K |
| Decrease in amount due to employees | -48.33K |
| Increase in deferred revenue | -138 |
| (Decrease) increase in deferred rent liability | 3.39K |
| NET CASH USED IN OPERATING ACTIVITIES | -16.22M |
| Decrease in restricted cash | |
| Purchase of equipment | -31.41K |
| Patent costs | -5.01K |
| NET CASH USED IN INVESTING ACTIVITIES | -36.41K |
| Payment for repurchase of preferred stock | |
| Proceeds from exercise of stock options and warrants | |
| Proceeds from sale of stock | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 15.75M |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | -507.72K |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD | 5.73M |
| CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD | 5.22M |
| Increase in accounts payable | |
| Increase in patent costs | |
| Total | |
| Increase in accounts payable for Equipment costs | |
| Increase in research and office equipment | |
| Total | |
| Decrease in derivative liabilities | |
| Increase in additional paid-in capital | |
| Total | |
| Increase in additional paid-in capital | |
| Decrease in additional paid-in capital | |
| Total | |
| Increase in derivative liabilities | |
| Increase in accumulated deficit | |
| Total | |
| Decrease in accrued expenses | |
| Increase in additional paid-in capital | |
| Total | |
| Cash expenditures for interest expense | 43.65K |
Entities mentioned with CVM
- FDA | View Related Stories »
- S3 | View Related Stories »
- Earnings | View Related Stories »
- ThinkEquity | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
